DSM-5: a fatal diagnosis?

Academic psychiatry, research ethics, and the drug industry

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3655 (Published 11 June 2013)
Cite this as: BMJ 2013;346:f3655

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Derek A Summerfield, honorary senior lecturer1
  1. 1Institute of Psychiatry, London SE5 8BB, UK
  1. derek.summerfield{at}slam.nhs.uk

In his article on DSM-5 (the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders), Gornall mentions Charles Nemeroff, a professor at Emory University.1 Nemeroff concealed huge payments made covertly to him by GlaxoSmithKline, makers of the antidepressant paroxetine, while lead investigator on a National Institutes of Health (NIH) study of that very drug.2 Nemeroff was …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL